|
|
Article: The American Journal of Psychiatry Publishes Data on Clinical Trial of Nalmefene in the Treatment of Pathological Gambling.
- Article from:
- PR Newswire
- Article date:
- February 3, 2006
|
Copyright informationCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ -- Somaxon Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of psychiatric and neurological disorders, today said that the February 2006 issue of the American Journal of Psychiatry features an article which describes the conduct and results of a four-month clinical trial investigating the efficacy and safety of one of its product candidates, oral nalmefene hydrochloride, an opioid antagonist, in reducing pathological gambling-related urges, thoughts and behaviors.
BioTie Therapies Corp. of Finland sponsored the trial, which was completed ...
Related newspaper, magazine, and journal articles:
|